Taiwan
· Delayed Price · Currency is TWD Medigen Vaccine Biologics Statistics
Total Valuation
Medigen Vaccine Biologics has a market cap or net worth of TWD 15.78 billion. The enterprise value is 14.28 billion.
| Market Cap | 15.78B |
| Enterprise Value | 14.28B |
Important Dates
The next estimated earnings date is Friday, November 1, 2024.
| Earnings Date | Nov 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Medigen Vaccine Biologics has 328.65 million shares outstanding. The number of shares has increased by 0.31% in one year.
| Shares Outstanding | 328.65M |
| Shares Change (YoY) | +0.31% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 0.21% |
| Owned by Institutions (%) | 3.28% |
| Float | 255.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.30 |
| PB Ratio | 4.10 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -20.58 |
| EV / Sales | 22.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -59.46 |
Financial Position
The company has a current ratio of 11.99, with a Debt / Equity ratio of 7.42.
| Current Ratio | 11.99 |
| Quick Ratio | 9.39 |
| Debt / Equity | 7.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.19 |
| Interest Coverage | -22.12 |
Financial Efficiency
Return on equity (ROE) is -16.64% and return on invested capital (ROIC) is -8.76%.
| Return on Equity (ROE) | -16.64% |
| Return on Assets (ROA) | -8.47% |
| Return on Capital (ROIC) | -8.76% |
| Revenue Per Employee | 6.05M |
| Profits Per Employee | -6.74M |
| Employee Count | 103 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0.29 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.60% in the last 52 weeks. The beta is 0.77, so Medigen Vaccine Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -34.60% |
| 50-Day Moving Average | 47.92 |
| 200-Day Moving Average | 56.12 |
| Relative Strength Index (RSI) | 50.27 |
| Average Volume (20 Days) | 744,406 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medigen Vaccine Biologics had revenue of TWD 623.45 million and -694.03 million in losses. Loss per share was -2.11.
| Revenue | 623.45M |
| Gross Profit | 415.57M |
| Operating Income | -742.18M |
| Pretax Income | -694.03M |
| Net Income | -694.03M |
| EBITDA | -624.74M |
| EBIT | -742.18M |
| Loss Per Share | -2.11 |
Balance Sheet
The company has 1.78 billion in cash and 285.56 million in debt, giving a net cash position of 1.49 billion or 4.54 per share.
| Cash & Cash Equivalents | 1.78B |
| Total Debt | 285.56M |
| Net Cash | 1.49B |
| Net Cash Per Share | 4.54 |
| Equity (Book Value) | 3.85B |
| Book Value Per Share | 11.70 |
| Working Capital | 2.31B |
Cash Flow
In the last 12 months, operating cash flow was -205.37 million and capital expenditures -34.89 million, giving a free cash flow of -240.26 million.
| Operating Cash Flow | -205.37M |
| Capital Expenditures | -34.89M |
| Free Cash Flow | -240.26M |
| FCF Per Share | -0.73 |
Margins
Gross margin is 66.66%, with operating and profit margins of -119.04% and -111.32%.
| Gross Margin | 66.66% |
| Operating Margin | -119.04% |
| Pretax Margin | -111.32% |
| Profit Margin | -111.32% |
| EBITDA Margin | -100.21% |
| EBIT Margin | -119.04% |
| FCF Margin | -38.54% |
Dividends & Yields
Medigen Vaccine Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.31% |
| Shareholder Yield | -0.31% |
| Earnings Yield | -4.40% |
| FCF Yield | -1.52% |
Stock Splits
The last stock split was on August 3, 2022. It was a forward split with a ratio of 1.48280574.
| Last Split Date | Aug 3, 2022 |
| Split Type | Forward |
| Split Ratio | 1.48280574 |